Cargando…

Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with Diabetes mellitus

Purpose: To determine the efficacy of systemic sodium-glucose co-transporter 2 inhibitors (SGLT2i) on diabetic macular edema (DME). Methods: The medical records of patients with DME with a central retinal thickness (CRT) ≥320 µm in men and 305 µm in women, more than 6 months after the initiation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatsumi, Tomoaki, Oshitari, Toshiyuki, Takatsuna, Yoko, Ishibashi, Ryoichi, Koshizaka, Masaya, Shiko, Yuki, Baba, Takayuki, Yokote, Koutaro, Yamamoto, Shuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146993/
https://www.ncbi.nlm.nih.gov/pubmed/35629361
http://dx.doi.org/10.3390/life12050692
_version_ 1784716698685800448
author Tatsumi, Tomoaki
Oshitari, Toshiyuki
Takatsuna, Yoko
Ishibashi, Ryoichi
Koshizaka, Masaya
Shiko, Yuki
Baba, Takayuki
Yokote, Koutaro
Yamamoto, Shuichi
author_facet Tatsumi, Tomoaki
Oshitari, Toshiyuki
Takatsuna, Yoko
Ishibashi, Ryoichi
Koshizaka, Masaya
Shiko, Yuki
Baba, Takayuki
Yokote, Koutaro
Yamamoto, Shuichi
author_sort Tatsumi, Tomoaki
collection PubMed
description Purpose: To determine the efficacy of systemic sodium-glucose co-transporter 2 inhibitors (SGLT2i) on diabetic macular edema (DME). Methods: The medical records of patients with DME with a central retinal thickness (CRT) ≥320 µm in men and 305 µm in women, more than 6 months after the initiation of diabetes mellitus treatment, were reviewed. The CRT and best-corrected visual acuity (BCVA) were evaluated before and after the initiation of systemic SGLT2i and non-SGLT2i treatments. Results: There were 24 eyes of 19 patients with DME that were treatment naïve or had not received treatments for the DME within four months before the initiation of SGLT2i. In these patients, the BCVA had a 0.31 ± 0.39 logarithm of the minimum angle of resolution (logMAR) units at the baseline, and it did not improve significantly at 0.26 ± 0.29 logMAR units after the initiation of SGLT2i (p = 0.56). However, the SGLT2i treatment significantly reduced the CRT from 423.3 ± 79.8 µm to 379.6 ± 69.5 µm (p = 0.0001). In the same evaluation of 19 eyes of 14 patients with DME that were initiated with non-SGLT2i agents, there was no significant difference between the baseline BCVA and the BCVA after the initiation of non-SGLT2i (p = 0.47). The CRT increased significantly after the initiation of non-SGLT2i (p = 0.0011). In three eyes in which the SGLT2i treatments were administered at the time of anti-vascular endothelial growth factor (VEGF) treatments, the anti-VEGF treatment alone had only a limited effect on the DME, but the reduction in the DME was enhanced after the addition of SGLT2i. Conclusions: These findings indicate that systemic SGLT2i can reduce DMEs, and they suggest that SGLT2i may be an additional treatment option to anti-VEGF treatments for eyes with DMEs.
format Online
Article
Text
id pubmed-9146993
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91469932022-05-29 Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with Diabetes mellitus Tatsumi, Tomoaki Oshitari, Toshiyuki Takatsuna, Yoko Ishibashi, Ryoichi Koshizaka, Masaya Shiko, Yuki Baba, Takayuki Yokote, Koutaro Yamamoto, Shuichi Life (Basel) Article Purpose: To determine the efficacy of systemic sodium-glucose co-transporter 2 inhibitors (SGLT2i) on diabetic macular edema (DME). Methods: The medical records of patients with DME with a central retinal thickness (CRT) ≥320 µm in men and 305 µm in women, more than 6 months after the initiation of diabetes mellitus treatment, were reviewed. The CRT and best-corrected visual acuity (BCVA) were evaluated before and after the initiation of systemic SGLT2i and non-SGLT2i treatments. Results: There were 24 eyes of 19 patients with DME that were treatment naïve or had not received treatments for the DME within four months before the initiation of SGLT2i. In these patients, the BCVA had a 0.31 ± 0.39 logarithm of the minimum angle of resolution (logMAR) units at the baseline, and it did not improve significantly at 0.26 ± 0.29 logMAR units after the initiation of SGLT2i (p = 0.56). However, the SGLT2i treatment significantly reduced the CRT from 423.3 ± 79.8 µm to 379.6 ± 69.5 µm (p = 0.0001). In the same evaluation of 19 eyes of 14 patients with DME that were initiated with non-SGLT2i agents, there was no significant difference between the baseline BCVA and the BCVA after the initiation of non-SGLT2i (p = 0.47). The CRT increased significantly after the initiation of non-SGLT2i (p = 0.0011). In three eyes in which the SGLT2i treatments were administered at the time of anti-vascular endothelial growth factor (VEGF) treatments, the anti-VEGF treatment alone had only a limited effect on the DME, but the reduction in the DME was enhanced after the addition of SGLT2i. Conclusions: These findings indicate that systemic SGLT2i can reduce DMEs, and they suggest that SGLT2i may be an additional treatment option to anti-VEGF treatments for eyes with DMEs. MDPI 2022-05-06 /pmc/articles/PMC9146993/ /pubmed/35629361 http://dx.doi.org/10.3390/life12050692 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tatsumi, Tomoaki
Oshitari, Toshiyuki
Takatsuna, Yoko
Ishibashi, Ryoichi
Koshizaka, Masaya
Shiko, Yuki
Baba, Takayuki
Yokote, Koutaro
Yamamoto, Shuichi
Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with Diabetes mellitus
title Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with Diabetes mellitus
title_full Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with Diabetes mellitus
title_fullStr Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with Diabetes mellitus
title_full_unstemmed Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with Diabetes mellitus
title_short Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with Diabetes mellitus
title_sort sodium-glucose co-transporter 2 inhibitors reduce macular edema in patients with diabetes mellitus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146993/
https://www.ncbi.nlm.nih.gov/pubmed/35629361
http://dx.doi.org/10.3390/life12050692
work_keys_str_mv AT tatsumitomoaki sodiumglucosecotransporter2inhibitorsreducemacularedemainpatientswithdiabetesmellitus
AT oshitaritoshiyuki sodiumglucosecotransporter2inhibitorsreducemacularedemainpatientswithdiabetesmellitus
AT takatsunayoko sodiumglucosecotransporter2inhibitorsreducemacularedemainpatientswithdiabetesmellitus
AT ishibashiryoichi sodiumglucosecotransporter2inhibitorsreducemacularedemainpatientswithdiabetesmellitus
AT koshizakamasaya sodiumglucosecotransporter2inhibitorsreducemacularedemainpatientswithdiabetesmellitus
AT shikoyuki sodiumglucosecotransporter2inhibitorsreducemacularedemainpatientswithdiabetesmellitus
AT babatakayuki sodiumglucosecotransporter2inhibitorsreducemacularedemainpatientswithdiabetesmellitus
AT yokotekoutaro sodiumglucosecotransporter2inhibitorsreducemacularedemainpatientswithdiabetesmellitus
AT yamamotoshuichi sodiumglucosecotransporter2inhibitorsreducemacularedemainpatientswithdiabetesmellitus